SALL4 and clear cell renal carcinoma: An additional report showed that SALL4 knockdown increased PTEN expression, inhibited downstream intermediate phosphorylation of AKT and GSK3β, and decreased vascular endothelial growth factor A (VEGFA) expression in clear cell renal cell carcinoma (ccRCC), providing convincing evidence that SALL4 is functionally critical in tumor progression and may be regarded as a drug target [55].